Asymptomatic SARS-CoV-2 Infection in Nursing Homes, Barcelona, Spain, April 2020

Blanca Borras-Bermejo,1 Xavier Martínez-Gómez,1 María Gutierrez-San Miguel, Juliana Esparalba, Andrés Antón, Elisabet Martin, Marta Selvi, María José Abadías, Antonio Román, Tomás Pumarola, Magda Campins, Benito Almirante

Author affiliations: Vall d’Hebron Hospital Universitari, Barcelona, Spain (B. Borras-Bermejo, X. Martínez-Gómez, M. Gutierrez-San Miguel, J. Esparalba, A. Antón, M.J. Abadías, A. Román, T. Pumarola, M. Campins, B. Almirante); Universitat Autònoma de Barcelona, Bellaterra, Spain (X. Martínez-Gómez, A. Antón, A. Román, T. Pumarola, M. Campins, B. Almirante); Servei Atenció Primària Muntanya, Barcelona (E. Martin); Centre d’Atenció Primària Sant Andreu, Barcelona (M. Selvi)

DOI: https://doi.org/10.3201/eid2609.202603

During the coronavirus disease pandemic in Spain, from April 10–24, 2020, a total of 5,869 persons were screened for severe acute respiratory syndrome coronavirus 2 at nursing homes. Among residents, 768 (23.9%) tested positive; among staff, 403 (15.2%). Of those testing positive, 69.7% of residents and 55.8% of staff were asymptomatic.

As of April 2020, Spain was one of the countries accounting for the most coronavirus disease (COVID-19) deaths (1). More than half of those deaths occur in persons >80 years of age (2), which highlights the vulnerability of the elderly. Moreover, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be easily spread within nursing homes, causing outbreaks with high associated mortality rate (3,4). By the beginning of April, the exponential increase of cases overwhelmed the healthcare system in Spain. In this context, rapid outbreak identification and early intervention in nursing homes was needed.

At Vall d’Hebron Hospital, a tertiary hospital in Catalonia, Spain, we conducted test-based screening as a containment measure to promptly implement effective prevention and control measures in nursing homes. We present the early results of a coordinated intervention with primary care teams in ≈6,000 residents and facility staff in nursing homes in our catchment area.

We evaluated 69 nursing homes that had a total census of 6,714 persons. We excluded previous laboratory-confirmed cases of COVID-19. During April 10–24, an integrated team of hospital and primary care staff obtained samples for SARS-CoV-2 testing from all residents and workers: nasopharyngeal and oropharyngeal swab samples both combined in the same collection tube with viral transport media. We used a commercial CE-IVD–marked, real-time reverse transcription PCR–based assay (Cobas SARS-CoV-2; Roche Diagnostics, https://www.roche.com) on a Cobas 6800 system.

Each nursing home director recorded any symptoms present at least 48 hours before the scheduled day of testing for all residents and staff. According to the World Health Organization case definition of a suspected case of COVID-19, a person was classified as symptomatic if fever or acute respiratory symptoms were present at any moment during the preceding 14 days. In the absence of either, the person was considered to be asymptomatic.

We obtained a total of 5,869 samples, 3,214 from residents and 2,655 from facility staff. Overall, 768 (23.9%) residents and 403 (15.2%) staff members tested positive for SARS-CoV-2 (Table). The presence of fever or respiratory symptoms during the preceding 14 days was recorded in 2,624 residents (81.6%) and 1,772 staff members (66.7%). Among those testing positive and for whom we had information about symptoms, 69.7% of the residents and 55.8% of staff were asymptomatic.

1These first authors contributed equally to this article.
On the basis of laboratory results, we planned specific infection prevention and control measures, adapted to facility characteristics in <72 hours. The most relevant measures included isolation of infected residents, establishing cohorted areas and designated staff, excluding infected staff from work, ensuring proper supply of personal protection equipment, and training staff about contact- and droplet-based precautions. We established coordinated follow-up evaluation with primary care teams and facility directors.

COVID-19 heavily affected nursing homes, causing uncountable deaths in Spain (5,6). Restriction policies for visitors in nursing homes were described as part of the state of emergency declared on March 14 (7), but a national guideline to reduce the risk for SARS-CoV-2 transmission in these settings was not available until March 24 (8). Moreover, despite knowledge of community transmission starting in late February, widespread testing for SARS-CoV-2 was not available until mid-April.

Our data show an overall high prevalence of SARS-CoV-2 infection in residents and staff, noting a high transmission in these settings. Specific aspects of nursing homes (shared rooms or bathrooms, physically or cognitively impaired residents requiring high-demand care, rotating staff working in different facilities) and a limited adoption of prevention and control measures as reported by our teams are some factors that may explain these results. Among those with known symptom status, we found a high proportion of asymptomatic cases: 69.7% of infected residents and 55.8% of infected staff.

Our study had several limitations. The ascertainment process could lead to misclassification due to atypical symptoms in the elderly. Furthermore, cross-sectional symptom assessment and testing did not allow us to differentiate between presymptomatic and asymptomatic cases. Nevertheless, these values are consistent with a study performed in a nursing facility in King County, Washington, USA, in which 56% of the residents testing positive were asymptomatic (9).

Given that presymptomatic and asymptomatic transmission has been demonstrated (10), our data suggest that asymptomatic cases could have had an important role in transmission dynamics. Symptoms-based approaches would have failed to correctly identify cases and therefore continued transmission. Furthermore, testing of facility staff should be included as part of the prevention and control measures, because they may contribute to sustained transmission.

In conclusion, the high prevalence of SARS-CoV-2 cases found in nursing homes highlights that this vulnerable population requires special attention and proactive interventions in coordination with the primary care teams. In the context of established community transmission of SARS-CoV-2, we recommend implementing test-based screening irrespective of symptomatology in nursing homes as the best approach to rapidly implement prevention and control measures.

**Acknowledgments**

We thank the Preventive Medicine and Epidemiology Department, Microbiology Department, and primary care teams, along with nursing home directors and staff, who actively collaborated in the implementation in a tight timeframe. We thank Friedel Laaf for the language review.

**About the Author**

Dr. Borras-Bermejo is a preventive medicine and public health physician working in the Preventive Medicine and Epidemiology Department in Vall d’Hebron University Hospital, Barcelona, Spain. Her research interests include vaccines and hospital infection prevention and control.

**References**

1. World Health Organization. Coronavirus disease (COVID-19) situation report 106. 2020 [cited 2020 June 4]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
2. Centro de Coordinación de Alertas y Emergencias Sanitarias. Dirección General de Salud Pública, Calidad e Innovación. Update 108. Coronavirus disease (COVID-19) [in Spanish]. 2020 May 17 [cited 2020 May 21]. https://bit.ly/2Ajvtt2
3. Comas-Herrera A, Zalakain J. Mortality associated with COVID-19 outbreaks in care homes: early international evidence. 2020 [cited 2020 May 21]. https://ltccovid.org/
Leuconostoc lactis and Staphylococcus nepalensis Bacteremia, Japan

Satoshi Hosoya, Satoshi Kutsuna, Daisuke Shiojiri, Saeko Tamura, Erina Isaka, Yuji Wakimoto, Hidetoshi Nomoto, Norio Ohmagari

Author affiliation: National Center for Global Health and Medicine, Tokyo, Japan

DOI: https://doi.org/10.3201/eid2609.191123

Leuconostoc lactis is a glycopeptide-resistant, gram-positive, facultative anaerobic coccus isolated from dairy products, whereas Staphylococcus nepalensis is coagulase-negative coccus that has not been identified as human pathogen. We report an instructive case of L. lactis and S. nepalensis bacteremia in a 71-year-old man who experienced Boerhaave syndrome after a meal.

Leuconostoc lactis is an intrinsically glycopeptide-resistant but ampicillin-susceptible, gram-positive, facultative anaerobic coccus (1) found in food products including dairy products, vegetables, and wine. L. lactis is a very rare pathogen associated with bloodstream infections (2). Staphylococcus nepalensis is a novobiocin-resistant coagulase-negative staphylococcus also found in food products, such as dry-cured ham and fish sauce, that has not been reported as a human pathogen (3–5). Neither L. lactis nor S. nepalensis is part of normal human bacterial flora (2,3).

A 71-year-old man with hypertension and hyperlipidemia sought care for upper abdominal pain and vomiting after a meal at his son’s restaurant. A computed tomography (CT) scan showed collapse of the lower esophagus wall and expansion of the mediastinum; medical staff diagnosed a spontaneous esophageal rupture and performed emergency surgery. Surgical findings demonstrated a 5 cm perforation of the lower esophagus with no rupture to the thoracic and abdominal cavity. The final diagnosis included Boerhaave syndrome, esophageal hiatus hernia, and mediastinitis. Two sets of blood culture taken on day 1 were positive for gram-positive cocci, which we identified by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry as L. lactis in an aerobic bottle (10.7 h to culture) and an anaerobic bottle (13.3 h to culture) and S. nepalensis in 1 anaerobic bottle (24.3 h to culture). The 2 bacteria were indications of true bacteremia; therefore, we escalated ampicillin/sulbactam (treatment to piperacillin/tazobactam for L. lactis (Appendix Table 1, https://wwwnc.cdc.gov/EID/